Abstract
In order to ensure commercial success, clinical drug development has to be medically sound while taking into account business needs. Clinical trials must be conducted in a multinational setting in compliance with regulatory standards and in a timely fashion. One way of achieving these goals is to develop a partnership with medical directors in the affiliate business units and involve their local staff in the clinical development process. In the partnership model which was developed by Rhone-Poulenc Rorer Clinical Development over the past three years, worldwide clinical development plans are discussed upfront with affiliate medical directors at a clinical development board that also manages clinical program execution. Thus, medically relevant international protocols are developed. Efficiency is improved by decentralizing appropriate parts of the study management process. High standards of quality are guaranteed via standard operating procedures and guidelines within a global quality system. Resource and capacity planning ensures that time and cost targets are achieved for key projects. Insourced resources are managed using performance indicators designed to accelerate development and control costs. Theperformance of this business model was evaluated on an ongoing basis against internal and external benchmarks and found to be a cost-effective and viable strategy for achieving the mission of Worldwide Clinical Development.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.